The clinical development of active immunotherapies has exploded in the last ten years. Checkpoint inhibitors, in particular PD-1 and PD-L1, have been integrated into standard-of-care across many cancer types. The CRI Anna-Maria Kellen Clinical Accelerator team has tracked the FDA approvals of these immunotherapies, noting both their increase in frequency and gradually expanding range of cancer types and stages.

Anti-PD-1/L1 Antibody Approvals by U.S. FDA


Timeline of Anti-PD-1/L1 Antibody Approvals by the FDA

Other IO Agent Approvals by U.S. FDA


Timeline of non-PD-1/PD-L1 Immuno-Oncology Agent Approvals by the FDA

Anti-PD-1/L1 Antibody Approvals by EU, Japan, and China


Timeline of Anti-PD-1/L1 Antibody Approvals by the European Medicines Agency (EMA) for the European Union (EU), National Medical Products Administration (NMPA) for China, and Pharmaceuticals and Medical Devices Agency (PMDA) for Japan.

IO Landscapes

More Resources

Data Sources: Cancer Research Institute (CRI) analytics derive from public data sources, including trade news, company press releases, academic publications, FDA announcements,, and conference reports, and proprietary data sources including, but not limited to, GlobalData. The analytical algorithm and visualizations are developed by and therefore sole property of Cancer Research Institute.

Subscribe to our email newsletter to receive the latest updates on our landscape analyses.

Do you want more information on the Clinical Accelerator? Contact us

*Immunotherapy results may vary from patient to patient.